Brookstone Capital Management Buys 27,362 Shares of AstraZeneca PLC (NASDAQ:AZN)

Brookstone Capital Management increased its stake in AstraZeneca PLC (NASDAQ:AZNGet Rating) by 456.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,363 shares of the company’s stock after purchasing an additional 27,362 shares during the period. Brookstone Capital Management’s holdings in AstraZeneca were worth $2,235,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. DB Wealth Management Group LLC acquired a new position in AstraZeneca during the 1st quarter valued at about $26,000. Parkside Financial Bank & Trust boosted its stake in AstraZeneca by 4,875.0% in the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after acquiring an additional 390 shares during the last quarter. Baltimore Washington Financial Advisors Inc. acquired a new stake in AstraZeneca during the 4th quarter worth $27,000. Fairfield Bush & CO. bought a new stake in shares of AstraZeneca during the 1st quarter valued at $28,000. Finally, Quent Capital LLC acquired a new position in shares of AstraZeneca in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 21.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on AZN shares. UBS Group cut AstraZeneca from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 14th. upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, July 11th. Argus upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, August 29th. Credit Suisse Group cut shares of AstraZeneca from an “outperform” rating to a “neutral” rating in a report on Thursday, September 15th. Finally, TheStreet lowered shares of AstraZeneca from a “b-” rating to a “c” rating in a report on Tuesday, August 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. According to data from, the company currently has a consensus rating of “Hold” and a consensus target price of $8,840.50.

AstraZeneca Trading Down 1.0 %

AZN opened at $57.40 on Wednesday. The stock has a market capitalization of $177.87 billion, a P/E ratio of -140.00, a P/E/G ratio of 1.12 and a beta of 0.44. The company has a current ratio of 0.96, a quick ratio of 0.67 and a debt-to-equity ratio of 0.74. AstraZeneca PLC has a 12 month low of $53.63 and a 12 month high of $71.70. The firm’s fifty day simple moving average is $64.20 and its 200 day simple moving average is $64.85.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were issued a $0.465 dividend. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 2.2%. AstraZeneca’s dividend payout ratio (DPR) is -221.95%.

About AstraZeneca

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.